Gilead slips 3.7% in earnings week
Gilead drops 3.7% as the buy signal's confirmation week closes red
Gilead slips 3.7% in earnings week
Our view last week
Gilead Sciences' shares closed the week up 3.4%, confirming the double bottom in the 122 area with a 6% intermediate rebound. The sell signal that had been running for months has finally lost its push: in its place, a fresh buy signal just kicked in. The weekly technical analysis shows a bullish picture, though with some caution -- buyer dominance is fading and earnings are just around the corner.
This week's summary
Gilead Sciences shares closed the week down 3.7%, slipping back toward the double bottom in the 122 area after the past weeks' rebound. Buyer dominance is fading and sellers ruled the last bar: the first confirmation week of the fresh buy signal closes negative. Our technical analysis also flags earnings, due this very week.
IQS Phase
39
ordinary
Signal Strength
47
medium · weak
Sizing
REDUCED
Ranking
#78 / 124
US stocks in progress
Trade P&L %
-3.70%
from signal to today
Rank position
ranks 78th among the 124 Longs already running for US stocks in our ranking, with a signal strength of 47 out of 100.
Sector context
SectorHealth Care
Benchmark ETFXLV
Sector regimein positive regime
Performanceweekly +0.92% · monthly +6.01%
GILD belongs to the health care sector (reference ETF XLV). The sector is classified in positive regime according to our weekly reading.
restricted Platinum content